Ticker
AGIO

Price
28.83
Stock movement up
+0.16 (0.56%)
Company name
Agios Pharm
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
1.58B
Ent value
1.63B
Price/Sales
214748.36
Price/Book
1.31
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-22.85%
3 year return
-8.25%
5 year return
-13.69%
10 year return
-
Last updated: 2022-11-24

DIVIDENDS

AGIO does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales214748.36
Price to Book1.31
EV to Sales214748.36

FINANCIALS

Per share

Loading...
Per share data
Current share count54.79M
EPS (TTM)-4.96
FCF per share (TTM)-5.52

Income statement

Loading...
Income statement data
Revenue (TTM)873.00
Gross profit (TTM)534.00
Operating income (TTM)-287.30M
Net income (TTM)-269.70M
EPS (TTM)-4.96
EPS (1y forward)-6.23

Margins

Loading...
Margins data
Gross margin (TTM)61.17%
Operating margin (TTM)-214748.36%
Profit margin (TTM)-214748.36%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash80.03M
Net receivables5.91M
Total current assets975.14M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment29.20M
Total assets1.34B
Accounts payable11.55M
Short/Current long term debt94.61M
Total current liabilities45.79M
Total liabilities128.41M
Shareholder's equity1.21B
Net tangible assets1.21B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-291.07M
Capital expenditures (TTM)8.77M
Free cash flow (TTM)-299.84M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-22.34%
Return on Assets-20.19%
Return on Invested Capital-22.12%
Cash Return on Invested Capital-24.59%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open28.87
Daily high29.06
Daily low28.17
Daily Volume318K
All-time high135.01
1y analyst estimate34.00
Beta1.33
EPS (TTM)-4.96
Dividend per share-
Ex-div date-
Next earnings date22 Feb 2023

Downside potential

Loading...
Downside potential data
AGIOS&P500
Current price drop from All-time high-78.65%-15.76%
Highest price drop-87.36%-56.47%
Date of highest drop14 Jun 20229 Mar 2009
Avg drop from high-52.29%-11.46%
Avg time to new high50 days13 days
Max time to new high1981 days1805 days
COMPANY DETAILS
AGIO (Agios Pharm) company logo
Marketcap
1.58B
Marketcap category
Small-cap
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Employees
390
Investor relations
-
SEC filings
CEO
Jacqualyn A. Fouse
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
The Joung Lab at Massachusetts General Hospital and Harvard Medical School has given birth to a new diagnostics startup. It's called SeQure Dx, and it aims to use tests to evaluate the potential that ...
November 17, 2022
The European Commission has approved Agios Pharmaceuticals Inc's (NASDAQ: AGIO) Pyrukynd (mitapivat) for PK deficiency in adult patients. Pyrukynd is a first-in-class, oral PK activator and the first ...
November 11, 2022
First and Only Disease-modifying Therapy for EU Patients with Rare Blood DisorderCAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field o...
November 10, 2022
How far off is Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO ) from its intrinsic value? Using the most recent financial...
November 9, 2022
Agios Pharmaceuticals (AGIO) posts narrower-than-expected Q3 loss while sales miss estimates. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.
November 4, 2022
– Long-term Data for PYRUKYND® (mitapivat) in Adults with Pyruvate Kinase (PK) Deficiency and Adults with Thalassemia Demonstrate Sustained Improvement in Hemoglobin, Markers of Hemolysis and Other Di...
November 3, 2022
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 14.86% and 29.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto...
November 3, 2022
– U.S. PYRUKYND® (mitapivat) Launch Provides Capability Building Platform to Support Expected Future Product Growth and Expansion; Net Revenue of $3.5 Million in Q3 – – Received Positive CHMP Opinion ...
November 3, 2022
Sagard Healthcare Partners Acquires Rights to Agios’ 5% Royalty on TIBSOVO® U.S. Net SalesCAMBRIDGE, Mass. and TORONTO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a ...
October 27, 2022
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare and genetically defined disea...
October 20, 2022
Next page